Life Sciences Industry Group

Jeff Howland - Corporate and Securities Team Leader

Jeff has extensive experience representing public and privately held life science, medical device, health care and other high technology businesses. His practice is concentrated in the areas of venture capital finance, securities regulation, corporate governance, mergers and acquisitions, spin-offs, technology transfer, licensing and complex research and development collaborations between pharmaceutical and biotech companies. His clients include publicly traded corporations, venture capital and private equity firms, universities, entrepreneurs and privately held technology businesses. Read more...

Jackie Camp

Jackie has extensive experience representing life science companies on both a transactional and general corporate basis. She specializes in finance transactions, from venture capital to mezzanine to syndicated bank financings, and is experienced in mergers and acquisitions, securities work and day-to-day advising of public and private companies. She has acted as outside general counsel to a publicly-held medical device manufacturer on acquisitions, divestitures, financings, securities law compliance, corporate governance and general business matters, venture capital financings of medical device and medical research companies, lender and borrower-side financings of medical products companies and representation of an international health sciences conglomerate in their senior and subordinated financings. Read more...

Ken Carroll

Ken is the Managing Member of Womble Carlyle’s Research Triangle Park office and a member of the Firm Management Committee. He is in the corporate and securities practice group and practices primarily in the areas of mergers, acquisitions and divestitures, joint ventures and strategic alliances. Ken has represented life science companies in these practice areas, as well as in connection with supply and distribution contracts. His experience also includes negotiating the sale of a stem cell research company, working on the sale of a major pharmaceutical manufacturing facility and representing life science companies engaged in biotherapeutics and health care consulting. Read more...

Greg Chabon

Greg is an experienced corporate and transactional attorney who represents clients in the pharmaceutical and health care industries in connection with joint ventures and co-development agreements, mergers & acquisitions, and licensing agreements, as well as a wide variety of general corporate matters. He has been lead attorney on co-development and other joint venture agreements for over-the-counter and prescription pharmaceutical products, including domestic and foreign commercialization agreements. Greg represents health care providers in corporate matters, merger and acquisition transactions, and joint venture arrangements, within the regulatory environment imposed by federal and state self-referral and anti-kickback laws. Read more...

Dean Rutley

Dean is an experienced corporate and transaction attorney who represents clients in the pharmaceutical, biotechnology and health care industries in connection with joint ventures and teaming agreements, mergers & acquisitions, venture capital and licensing agreements as well as a wide variety of corporate matters. He has served as lead attorney on venture capital and private equity financings of life sciences companies and on co-development and other joint venture agreements in the biotech and pharmaceutical industries. His experience includes having represented ASM Resources, the venture capital arm of the American Society of Microbiology, as lead attorney in its equity investments and fund formation work. Dean also has worked with various life science companies in connection with their corporate requirements, including executive compensation arrangement, stock option plans and counseling on board related matters. Read more...

Clint Richardson

Clint has worked with medical device and pharmaceutical companies for three decades, beginning in 1977 as part of a legal team that advised a private Texas-based device manufacturer through its growth years, public offerings and NYSE listing. He has, similarly, provided start-up to public company representation for a leading tissue science company, also listed on the NYSE. His work with private and public life science companies has involved private fundraisings, initial and follow-on public offerings, governance counseling, technology and trade secrecy advice, licensing, distribution, joint ventures, mergers, acquisitions and spin-off strategies. Over the years, he has also helped clients respond to warning letters, recalls and investigations by the SEC, FDA and CDC as well as shareholder and derivative lawsuits. Clint's interest in life science companies is matched with a passion for the process of private capital fundraising, which he uses to assist life science companies through the critical fundraising process. He is a founder and director of the oldest and largest venture capital trade association in the Southeast and author of a critically acclaimed series of Growth Company Guides for entrepreneurs, the first of which was published in 1987 as The Venture Magazine Complete Guide to Venture Capital. Read more...

Mark Henriques

Mark has extensive experience helping pharmaceutical companies resolve business and contractual disputes. Mark has represented both API manufacturers and drug product distributors. He is familiar with the FDA’s drug approval process and issues surrounding Good Manufacturing Practices. In his 15 years with Womble Carlyle’s Business Litigation group, Mark has had extensive trial experience and has developed the ability to explain complicated life-science issues to judges, arbitrators and juries. Read more...

Chris Gyves

Chris represents life science and other technology businesses and concentrates his practice in the areas of venture capital finance, securities regulation, corporate governance, and mergers and acquisitions. His clients include publicly traded corporations, privately held technology businesses, private equity firms, universities and entrepreneurs. Chris has a particular interest in start-up ventures and received an entrepreneurship grant from the Kauffman, Price and Angell Foundation while earning his M.B.A. Chris’s venture capital experience covers the range of small, seed-stage investments by angel investors through large investments by sophisticated national and international institutional investors. Read more...